ENGLEWOOD, Fla., July 26, 2005 (PRIMEZONE) -- SinoFresh HealthCare, Inc. (OTCBB:SFSH) today released published results of in vitro laboratory experiments demonstrating the ability of its advanced nasal cleansing spray, SinoFresh(tm) Nasal Spray, to kill specific highly infectious respiratory viruses. The published results are available on the company's website, www.sinofresh.com.
The laboratory experiments, performed in collaboration with the Lovelace Respiratory Research Institute (LRRI) of Albuquerque, NM, were intended to demonstrate SinoFresh's(tm) potential as a first line defense against infectious respiratory disease as a result of inhaled pathogens. Viruses are acknowledged as the most frequent cause of acute respiratory infection (ARI) in healthy humans. The two viruses selected for the studies, adenovirus and respiratory syncytial virus (RSV), are responsible for a high percentage of ARI cases in infants and young children worldwide. The two strains are also common causes of community-acquired respiratory infections and, in particular, RSV is an important pathogen of elderly and immunocompromised individuals. Suitable vaccines are not currently available for either virus.
"The commercially available version of SinoFresh(tm) showed excellent virucidal activity against both pathogens," explained William Wilferth, Vice President of R&D for SinoFresh HealthCare. "This is further supportive data to present to the FDA at our upcoming Pre-IND meeting where we will determine our course of action to gain drug status for a prescription version of SinoFresh(tm)."
SinoFresh HealthCare will next move to repeat the studies in mammalian-based models through its research collaboration with LRRI. The goal of those studies is to demonstrate the potential for prophylactic viral defense as well as the inhibition of the spread of viral infections. Those studies are scheduled to commence within the next 30 days.
"The world is changing rapidly in terms of viral infection and transmission," said Charles Fust, Chairman and CEO of SinoFresh HealthCare. "In only a matter of hours a viral pathogen can leap from one continent to another, quickly reaching epidemic proportions. In the more than eight years since we began scientific studies with SinoFresh(tm), we've consistently shown that our concept extends well beyond symptomatic treatment and into the category of prevention."
About SinoFresh HealthCare, Inc.
SinoFresh HealthCare, Inc. is a developer and marketer of innovative therapies for conditions of the upper respiratory system. The Company is researching broad-spectrum antiseptic approaches to reducing viral, bacterial, and fungal organisms that are suspected to cause pathogenesis of the mouth, nose, and throat. The Company holds many patents and patent applications on its innovative pharmaceutical technology and relies upon a distinguished panel of medical experts and a management team experienced in the bio-pharmaceutical arena.
The Company's lead product, SinoFresh(tm) Nasal Spray, is a hygienic cleansing spray that kills germs and removes other nasal-sinus irritants. The Company is also researching how antiseptic cleansing may aid in alleviating sinus distress, a problem that may affect 37 million Americans annually. SinoFresh(tm) Nasal Spray Care is available nationwide in Wal-Mart, Walgreens, Rite Aid, CVS, Sav-on drugs, Osco Drug and other drug, grocery and mass merchandise retailers. More information is available at www.sinofresh.com.
About The Lovelace Respiratory Research Institute
Lovelace Respiratory Research Institute, located in Albuquerque, New Mexico, is a not-for-profit research institution founded in 1947 by Dr. William Randolph Lovelace II. It is one of the nation's largest independent basic science research institutions and the only one focused solely on respiratory health. Scientists at LRRI are committed to eradicating respiratory diseases through research aimed at understanding their causes and biological mechanisms, eliminating exposures to causal agents, and developing more effective treatments. More information is available at www.lrri.org.
Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements speak only as of the date on which such statements are made and involve risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission, including risks summarized in the Company's Annual Report on Form 10-KSB for its fiscal year ended December 31, 2004 (file No. 0-49764). The Company's actual results could differ materially from such forward-looking statements. The Company undertakes no obligation to update any forward-looking statement or statements to reflect new events or circumstances or future developments.
(Note) SinoFresh(tm) is a trademark of SinoFresh HealthCare, Inc.